Hyperlipidemia News and Research

RSS

Hyperlipidemia, hyperlipoproteinemia or dyslipidemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood. Lipids (fatty molecules) are transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism.

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

26 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

The American Association of Clinical Endocrinologists today announced the publication of its comprehensive diabetes management algorithm created to guide primary care physicians, endocrinologists and other health care professionals in the treatment of prediabetes and type 2 diabetes mellitus patients.

20 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

New Orleans residents continue to face increased risk of heart attack post-Katrina

New Orleans residents continue to face a three-fold increased risk of heart attack post-Katrina-a trend that has remained unchanged since the storm hit in 2005, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.

7 Mar 2013

GP consultations: an interview with Associate Professor Helena Britt, University of Sydney

Well it hasn’t varied at all over the last 15 years, which I find pretty amazing because we’ve been through a lot of changes in general practice. Yet, the average length of consultation, as measured from a start to finish time, in a sample of 40,000 consultations in Australia in a year, shows that the average is 15 minutes and the median is 13 minutes.

4 Mar 2013

Counting the cost of bariatric surgery

Bariatric surgery for obese patients is not cost-saving relative to medical care, shows a 6-year follow-up study in JAMA Surgery.

28 Feb 2013

Bipolar disorder associated with increased hypertension risk

Taiwanese individuals with bipolar disorder are at an increased risk for hypertension when compared with the general population, research shows.

28 Feb 2013

Heightened stroke risk for patients with sleep apnea and atrial fibrillation

Atrial fibrillation may play an intermediary role in the relationship between obstructive sleep apnea and stroke, research findings suggest.

25 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Researchers discover miR-27b that regulates lipid levels in the blood

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia-abnormal blood cholesterol levels that can contribute to heart disease.

11 Feb 2013

Liver gene found to regulate cholesterol and fat blood levels

Researchers have identified a microRNA liver gene, miR-27b, which regulates lipid (cholesterol or fat) levels in the blood. This regulator gene controls multiple genes involved in dyslipidemia—abnormal blood cholesterol levels that can contribute to heart disease.

7 Feb 2013

Hyperlipidemia News and Research

Further Reading

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

NAFLD is an independent predictor of cardiovascular risk

Perosphere, Daiichi Sankyo sign clinical trial agreement

AACE publishes comprehensive diabetes management algorithm to treat prediabetes, T2DM patients

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

New Orleans residents continue to face increased risk of heart attack post-Katrina

GP consultations: an interview with Associate Professor Helena Britt, University of Sydney

Counting the cost of bariatric surgery

Bipolar disorder associated with increased hypertension risk

Heightened stroke risk for patients with sleep apnea and atrial fibrillation

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Researchers discover miR-27b that regulates lipid levels in the blood

Liver gene found to regulate cholesterol and fat blood levels

Empowered patients cost health systems less

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Hypertensive pregnancies need rigorous follow up

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Hypertensive pregnancies need rigorous follow up

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News